GRAIL has developed a methylation-based technology for research purposes only (RUO). The new technological solution analyses cell-free DNA (cfDNA) obtained from peripheral blood for cancer signal interrogation using the company’s targeted methylation platform. Potential research applications include prognosis, identification of minimal residual disease, and recurrence monitoring.
Related post: India to reduce increasing cancer burden by implementing robotics
GRAIL intends to produce a multi-cancer early detection blood test and advance scientific understanding of cancer biology by combining next-generation sequencing, population-scale clinical investigations, and computer and data science. GRAIL CEO Bob Ragusa commented: “GRAIL’s unique methylation technology and bioinformatics capabilities are well suited for circulating tumour DNA analysis across the cancer continuum. We are excited to further leverage our methylation platform and introduce our RUO technology solution for cancer prognosis, minimal residual disease, and recurrence monitoring and biomarker discovery.”
